Erik Popping, LL.M
Erik Popping joined Intravacc in January 2016. He has more than 14 years of experience within the pharmaceutical / healthcare industry as corporate and legal counsel. Before Erik joined Intravacc, he was Corporate & Legal counsel at the Hal Allergy Group. Prior to that he was the Legal Counsel of the Netherlands Vaccine Institute, a predecessor of Intravacc. He holds a Master’s degree in law (LL.M.) (Radboud University) and a Bachelor degree in business administration (HAN University of applied sciences).
Prof. Dr. Virgil Schijns
Chief Scientific Officer
Prof. Dr. Schijns joined Intravacc in November 2020. He was appointed special Professor in Immunology and Virology at North Carolina State University (NCSU) USA, in 2002, and Guest Professor of Immune Intervention at Wageningen University, The Netherlands, Department Cell Biology & Immunology in 2008. Since 2013, he has been Guest Professor at Strathclyde University, Glasgow, United Kingdom.
Virgil also has extensive experience in the Life Science and Biotech sector. He is the CSO of Epitopoietic Research Corporation S.A. in Namur, Belgium. Before that, he was principal Immunologist of Nobilon and Head of Vaccine Technology and Immunology at Intervet-AKZONOBEL.
Daniëlle Lankveld, DVM, PhD
Chief Operating Officer
Daniëlle is Chief Operational Officer of Intravacc since 2017. As a doctor in veterinary medicine she started her career in 1995 as a resident in equine surgery at the former Department of General and Large Animal Surgery of the Utrecht University. After completing this she continued her career as a veterinary anesthetist for the same department and obtained her PhD in 2007. In this year she moved to the National Institute of Public Health to work as both a researcher in nanotoxicology and an assessor of human medical dossiers for cardiovascular medicine. In 2011 Daniëlle became Manager of the Animal Research Center of the former Netherlands Vaccine Institute and member of the management team. In 2013, when the Animal Research Center became part of Intravacc, Daniëlle moved to the position of Chief Development Officer until 2017 when she became the COO.
Minke Wessels, MA
Minke Wessels joined Intravacc in September 2019. She brings more than 15 years of HR experience to Intravacc. After her Master degree in International Law at Leiden University, she started out as Team manager at the ING Bank. Five years into the job she chose a new career path within HR, to pursue her interests in individual & group development and change management. Before joining Intravacc, she was Sr. HR Business Partner at Nationale-Nederlanden. Minke is an experienced coach and trainer and she has a track record in creating a culture of collaboration and managing change.
Michiel Stork, PhD.
Vice President Business Development
Michiel started his current position as VP business development in July 2020 and works at Intravacc for over 9 years. Trained in molecular microbiology he first came in contact with vaccines in 2005. He worked in this field ever since. He started with antigen discovery and animal models followed by vaccine design and process development. This allowed him to work on the complete chain from lead finding up to clinical trials. Prior to his current position he was head of the Process Development Bacterial Vaccine department at Intravacc, where he focused on the design and upscaling of processes for conjugate and vesicle vaccines. During this time he studied the biogenesis of outer membrane vesicle vaccines to unravel the mechanism of formation and subsequent yield increases.
Elly van Riet
Vice President Research & Development
Elly has been working at Intravacc since 2013, and has been Vice-President of R&D since November 2020. She earned her MSc as an engineer in biotechnology at Wageningen University and Research Centre, followed by a PhD in immunology at the Department of Parasitology at Leiden University Medical Centre. During her PhD she got involved in vaccine research when she studied the effect of helminth infections on the immune responses to vaccination in Gabonese children. She continued vaccine related research as a postdoc at the Leiden Academic Centre for Drug Research where she was involved in designing nanoparticle vaccines for transcutaneous and intranasal delivery. She was granted a postdoctoral fellowship to investigate human immune responses to intranasal administration of influenza vaccines at the Influenza Virus Research Center of the National Institute of Infectious Diseases in Tokyo. In 2013 she joined Intravacc as Head of the department of Clinical Development.
Join our Community
Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.
Subscribe to our news update
Stay up to date with the latest developments, and be the first to receive our news updates and announcements.